Press Releases
Filter By Year
December
November
-
November 29, 2022
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations -
November 28, 2022
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer -
November 15, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
November 03, 2022
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 -
November 02, 2022
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients -
November 01, 2022
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
October
-
October 27, 2022
Gilead Sciences Announces Third Quarter 2022 Financial Results -
October 24, 2022
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities -
October 20, 2022
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers -
October 18, 2022
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022 -
October 17, 2022
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma -
October 17, 2022
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies -
October 13, 2022
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022 -
October 11, 2022
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer -
October 03, 2022
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
September
-
September 22, 2022
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines -
September 20, 2022
Gilead Sciences Completes Acquisition of MiroBio -
September 16, 2022
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma -
September 16, 2022
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19 -
September 15, 2022
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline -
September 13, 2022
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity -
September 07, 2022
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study -
September 06, 2022
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) -
September 04, 2022
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
August
-
August 29, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
August 29, 2022
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022 -
August 22, 2022
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option -
August 17, 2022
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care -
August 15, 2022
Gilead to Acquire Remaining Worldwide Rights of Trodelvy® -
August 15, 2022
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study -
August 09, 2022
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency -
August 04, 2022
Gilead Sciences to Acquire MiroBio -
August 02, 2022
Gilead Sciences Announces Second Quarter 2022 Financial Results
July
-
July 28, 2022
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection -
July 22, 2022
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) -
July 22, 2022
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19 -
July 21, 2022
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic -
July 20, 2022
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity -
July 19, 2022
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir) -
July 12, 2022
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 -
July 12, 2022
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
June
-
June 28, 2022
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma -
June 27, 2022
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor -
June 27, 2022
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases -
June 24, 2022
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV -
June 23, 2022
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks -
June 21, 2022
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 -
June 06, 2022
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC -
June 04, 2022
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma -
June 04, 2022
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL) -
June 04, 2022
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients -
June 03, 2022
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity -
June 02, 2022
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
May
-
May 19, 2022
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report -
May 17, 2022
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting -
May 16, 2022
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV -
May 02, 2022
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
April
-
April 28, 2022
Gilead Sciences Announces First Quarter 2022 Financial Results -
April 26, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
April 25, 2022
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 -
April 24, 2022
Several New Studies Presented at ECCMID 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 -
April 19, 2022
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland -
April 14, 2022
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022 -
April 11, 2022
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies -
April 01, 2022
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
March
-
March 28, 2022
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere -
March 07, 2022
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer -
March 01, 2022
Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatibility Issues
February
-
February 16, 2022
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor -
February 11, 2022
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022 -
February 11, 2022
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults -
February 11, 2022
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies -
February 08, 2022
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs -
February 03, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
February 01, 2022
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend -
February 01, 2022
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
January
-
January 31, 2022
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome -
January 25, 2022
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine -
January 21, 2022
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression -
January 18, 2022
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022 -
January 10, 2022
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Filter By Year